FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs

FDA's announcement Aug. 24 that it is reviewing adverse event reports of liver injury related to orlistat - the active ingredient in GlaxoSmithKline's weight-loss product alli could threaten the drug's already slipping sales.